XLO vs. ESPR, INMB, INBX, ACTU, IPHA, CYBN, LFVN, AARD, NBTX, and MOLN
Should you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Esperion Therapeutics (ESPR), INmune Bio (INMB), Inhibrx (INBX), Actuate Therapeutics (ACTU), Innate Pharma (IPHA), Cybin (CYBN), LifeVantage (LFVN), Aardvark Therapeutics (AARD), Nanobiotix (NBTX), and Molecular Partners (MOLN). These companies are all part of the "pharmaceutical products" industry.
Xilio Therapeutics vs.
Esperion Therapeutics (NASDAQ:ESPR) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, community ranking, profitability, earnings, risk, media sentiment, institutional ownership and valuation.
Esperion Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500.
Xilio Therapeutics has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.
47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 1.0% of Esperion Therapeutics shares are held by insiders. Comparatively, 5.2% of Xilio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Esperion Therapeutics had 16 more articles in the media than Xilio Therapeutics. MarketBeat recorded 17 mentions for Esperion Therapeutics and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.87 beat Esperion Therapeutics' score of 0.67 indicating that Xilio Therapeutics is being referred to more favorably in the news media.
Xilio Therapeutics has a net margin of 0.00% compared to Esperion Therapeutics' net margin of -29.37%. Esperion Therapeutics' return on equity of 0.00% beat Xilio Therapeutics' return on equity.
Esperion Therapeutics received 618 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Xilio Therapeutics an outperform vote while only 70.23% of users gave Esperion Therapeutics an outperform vote.
Esperion Therapeutics presently has a consensus price target of $6.42, indicating a potential upside of 542.05%. Xilio Therapeutics has a consensus price target of $4.00, indicating a potential upside of 422.40%. Given Esperion Therapeutics' higher probable upside, equities analysts plainly believe Esperion Therapeutics is more favorable than Xilio Therapeutics.
Summary
Esperion Therapeutics and Xilio Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Xilio Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xilio Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:XLO) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy XLO Stock Free XLO Stock Alerts